Mark Messak

Mark Messak

Auto-generated profile, based on publicly available information

Mark Messak

Faculty of Medicine, Helwan University, Helwan, Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
MMMark Messak
Mark Messak
AAAhmed Abdelmageed
Ahmed Abdelmageed
ASAbdelrahman A. Senbel
Abdelrahman A. Senbel
YKYoussef A. Khattab
Youssef A. Khattab
YMYoussef Mandour
Youssef Mandour
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
Recent trends suggest exploring the repurposing of different drugs for Parkinson’s disease patients (PD). One of these drugs is Glucagon-like peptide-1 (GLP-1), a medication used to treat type 2 diabetes mellitus. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of different forms of GLP-1 agonists on motor and non-motor functions of PD patients during ON-medication and OFF-medication states. A literature search was conducted through PubMed, Scopus, Web of Science, OVID, Cochrane Central, and Google Scholar using relevant keywords. Quality assessment was performed using the Risk of Bias-2 (RoB-2) domains. Statistical analysis included calculating the mean difference (MD) and the corresponding 95% confidence intervals (CIs) using Review Manager 5.4.1. Four randomized controlled trials (RCTs) testing three different forms of GLP-1 agonists with a total of 514 patients were included in the study. GLP-1 agonists significantly improved motor function during the OFF-medication state (MD = − 3.29, 95% CI [− 5.17 to − 1.42], P = 0.0006). It does not show improvement in quality of life assessed by PDQ-39 (MD = − 0.54, 95% CI [− 2.07 to 0.99], P = 0.49). None of the adverse effects stated in the RCTs were higher in the GLP-1 agonists group except for nausea (RR = 1.98, P = 0.0008), vomiting (RR = 6.65, P = 0.0008), constipation (RR = 1.45, P = 0.01), and weight loss (RR = 2.11, P = 0.03). This systematic review and meta-analysis provide evidence that GLP-1 agonists could improve the motor function of PD patients. However, safety is still of concern. Further high-quality studies with standardized protocols and larger sample sizes are needed to confirm our findings.

9 March 2026 in Advances in Health Sciences Education
Verified
Journal Article
Open access
PDF file
YOYusof Mohamed Omar
Yusof Mohamed Omar
YKYoussef A. Khattab
Youssef A. Khattab
AAAhmed Abdelmageed
Ahmed Abdelmageed
MMMark Messak
Mark Messak
YMYoussef Mandour
Youssef Mandour
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
Impostor phenomenon (IP) is widely cited as a significant challenge in medical education, yet its conceptual and methodological foundations are unstable, hindering a clear understanding of its true scope and impact. Thus, this systematic review and meta-analysis aimed to first establish a pooled prevalence of IP among medical students, and second, to critically appraise the measurement tools and definitions used in the literature. We systematically searched PubMed, Scopus, Web of Science, and CINAHL through July 2025 for all studies quantitatively assessing IP prevalence in medical students. Using a random-effects model, we analyzed data from 34 studies, including 9,550 participants. The overall pooled prevalence of IP was 49% (95% CI [0.43–0.54]), but this figure is complicated by extreme heterogeneity across studies (I 2 =95.6%, P < 0.001) despite multiple sensitivity analyses. Subgroup analyses revealed significant prevalence differences by gender (females 51% vs. males 40%; P = 0.021), geographic region ( P < 0.001), and the measurement tool used ( P < 0.001). The qualitative synthesis suggested associations between IP and negative mental health outcomes, including anxiety, depression, and burnout. Nevertheless, the variance driven by different measurement tools suggests that researchers may not be consistently measuring the same construct. The reliance on unvalidated cutoffs further weakens the validity of prevalence estimates. We conclude that while IP is clearly a prevalent concern, the construct’s weak theoretical grounding and inconsistent measurement impede meaningful progress. Advancing this area of medical education research requires a foundational shift toward conceptual clarity and methodological rigor.

15 May 2026 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
MMMark Messak
Mark Messak
AAAhmed Abdelmageed
Ahmed Abdelmageed
AAAhmed Noureldeen Abbas
Ahmed Noureldeen Abbas
YMYoussef Mandour
Youssef Mandour
ATAhmed Talkhan
Ahmed Talkhan
Ahmed NegidaAhmed Negida
Ahmed Negida

23 October 2026
Verified
Book Chapter
Closed access
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
MMMark Messak
Mark Messak
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
MKMrinmoy Kundu
Mrinmoy Kundu

21 July 2026 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
MMMark Messak
Mark Messak
YOYusof Mohamed Omar
Yusof Mohamed Omar
NMNada Mosad
Nada Mosad
OAOmar Ahmed
Omar Ahmed
HMHamdy A. Makhlouf
Hamdy A. Makhlouf
Essential tremor (ET) is a common movement disorder; its management remains challenging despite the availability of multiple treatment options. Pharmacological therapies are often limited in efficacy and tolerability, while surgical options, although effective, are invasive and expensive. Peripheral nerve stimulation (PNS) has emerged as a non-invasive neuromodulation approach. However, different stimulation protocols, small samples, and inconsistent outcome reporting preclude firm conclusions. Therefore, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of PNS for ET. A literature search was conducted through PubMed, Scopus, Web of Science, and Cochrane CENTRAL databases till January 2026. The primary outcome was the change in tremor intensity, as measured by the TETRAS Performance Scale (TETRAS-PS). Secondary outcomes included functional disability, assessed by the Bain and Findley Activities of Daily Living (BF-ADL) scale, clinical improvement assessed using the clinical global impression – improvement (CGI-I) scale, as well as safety outcomes. Quality assessment was performed using the Risk of Bias-2 (RoB-2) and the NIH single-arm tools. Certainty of evidence was assessed using GRADE approach. A meta-analysis was performed, calculating the mean difference (MD) with 95% confidence intervals (CIs) using Review Manager 5.4.1. Twelve studies, involving 914 participants, met the inclusion criteria, including four RCTs. Our analysis of RCTs demonstrated that active PNS produced a statistically significant reduction in tremor intensity (TETRAS-PS; MD=-0.92, 95%CI [-1.63 to -0.21], P = 0.01, I2 = 0) and an improvement in functional outcomes (BF-ADL; MD=-1.90, 95%CI [-2.97 to -0.83], p = 0.0005, I2 = 0). Benefits were observed immediately and persisted for up to three months in longitudinal studies. Adverse events were generally mild and limited mainly to transient skin irritation; no device-related serious adverse events were reported. PNS was associated with short-term reduction in tremor severity and functional impairment in patients with ET, with an overall acceptable safety profile, suggesting that it may serve as a middle ground option between pharmacotherapy and invasive neurosurgical approaches. However, further larger and longer randomized trials with refined sham controls are needed to confirm its efficacy, durability, and optimize stimulation strategies. CRD420261282826.

23 October 2026
Verified
Book Chapter
Closed access
AAAbdallah Abbas
Abdallah Abbas
CACeline Abboud
Celine Abboud
AAAshrakt H. Abdelhamid
Ashrakt H. Abdelhamid
DADina Essam Abo-Elnour
Dina Essam Abo-Elnour
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
AWAl-Hassan Soliman Wadan
Al-Hassan Soliman Wadan